InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
9
T+90 hit rate
20%
T+90 mean return
-17.4%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by GIVEN DOUGLAS B, Director. Insider active across 2 companies, notably Arrowhead Pharmaceuticals, INC.. In total, 16 filings have been published. Split: 0 buy · 9 sells. Total volume traded: €1.7m. Activity tracked since 22 June 2021. The latest transaction was disclosed on 16 December 2024 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations16 total
5,000 shares@ US$21.905.1% of flowCommon StockSEC:0001628280-24-051924:0
1,100 shares@ US$38.551.9% of flowCommon StockSEC:0001628280-24-001425:1
1,811 shares@ US$37.763.0% of flowCommon StockSEC:0001628280-24-001425:0
14,987 shares@ US$25.4116.9% of flowCommon StockSEC:0001628280-23-041962:0
6,500 shares@ US$40.9011.8% of flowCommon StockSEC:0001628280-23-016560:0
875 shares@ US$32.621.3% of flowCommon StockSEC:0001209191-23-014275:0
7,867 shares0Common StockSEC:0001209191-23-003075:0
6,400 shares0Common StockSEC:0001209191-22-002590
6,400 shares0Common StockSEC:0001209191-22-002590:0
655 shares0Common StockSEC:0001209191-21-071563
655 shares0Common StockSEC:0001209191-21-071563:0
5,000 shares@ US$65.240.0026% mcap22.5% of flowCommon StockSEC:0001209191-21-055474:0
5,000 shares@ US$65.2413.5% of flowCommon StockSEC:0001209191-21-055474
4,500 shares@ US$89.2116.5% of flowCommon StockSEC:0001209191-21-043051
4,500 shares@ US$89.210.0031% mcap27.5% of flowCommon StockSEC:0001209191-21-043051:0
35,000 sharesCommon StockSEC:0001209191-16-088054:0
16 of 16 declarations
About GIVEN DOUGLAS B
Douglas B. Given is a Board Member at ARROWHEAD PHARMACEUTICALS, INC. He contributes to the strategic direction of the company, participating in key decisions that influence its development. His expertise in the biopharmaceutical sector is valuable to the board, enabling ARROWHEAD to navigate effectively in a competitive environment.
